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ABSTRACT
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) (PL) is a
naturally occurring yellow pigment found in the plants of the
Plumbaginaceae, Droseraceae, Ancistrocladaceae, and Dion-
cophyllaceae families. It has been reported that PL exhibits
anticarcinogenic, anti-inflammatory, and analgesic activities.
However, the mechanism underlying its anti-inflammatory ac-
tion remains unknown. In the current study, we investigated
and characterized the anti-inflammatory and analgesic effects
of PL orally administrated in a range of dosages from 5 to 20
mg/kg. We also examined the role of nuclear factor B (NF-B)
and proinflammatory cytokines and mediators in this effect. The
results showed that PL significantly and dose-dependently
suppressed the paw edema of rats induced by carrageenan
and various proinflammatory mediators, including histamine,
serotonin, bradykinin, and prostaglandin E2. PL reduced the
number of writhing episodes of mice induced by the intraperi-
toneal injection of acetic acid, but it did not reduce the writhing
episode numbers induced by MgSO4 in mice or prolong the
tail-flick reaction time of rats to noxious thermal pain. Mecha-
nistic studies showed that PL effectively decreased the pro-
duction of the proinflammatory cytokines interleukin 1, inter-
leukin 6, and tumor necrosis factor . It also inhibited the
expression of the proinflammatory mediators inducible nitric-
oxide synthase and cyclooxygenase 2, whereas it did not inhibit
the expression of cyclooxygenase 1. Further studies demon-
strated that PL suppressed inhibitor of B phosphorylation
and degradation, thus inhibiting the phosphorylation of the p65
subunit of NF-B. This study suggests that PL has a potential to
be developed into an anti-inflammatory agent for treating in-
flammatory diseases.
Introduction
Inflammation has been demonstrated at the root of almost
all chronic diseases, such as cancer, cardiovascular diseases,
and autoimmune diseases, and huge efforts and resources
are dedicated to the development of anti-inflammatory
drugs. Nuclear factor B (NF-B) plays a critical role in the
pathogenesis of inflammation, and a variety of drugs de-
signed to treat human inflammatory disease are focused on
the inhibition of NF-B activation (Tak and Firestein, 2001).
Under normal conditions, NF-B is present in the cytoplasm
as an inactive heterotrimer consisting of three subunits: p50,
p65, and inhibitor of B (IB). Upon external stimuli, such
as mitogens, inflammatory cytokines, ultraviolet irradiation,
ionizing radiation, viral proteins, bacterial lipopolysaccha-
rides, and reactive oxygen species, IB undergoes phosphor-
ylation that is mediated through the activation of the IB
kinase (IKK) complex (Ducut Sigala et al., 2004) and ubiq-
uitination-dependent degradation by the 26S proteasome,
thus exposing nuclear localization signals on the p50–p65
heterodimer, leading to nuclear translocation and binding to
DNA. The binding of NF-B with DNA results in the tran-
scription of the NF-B-regulated genes (Aggarwal, 2004) and
induces the transcription of proinflammatory mediators,
such as inducible nitric-oxide synthase (iNOS), cyclooxygen-
ase (COX) 2, tumor necrosis factor (TNF) , interleukin (IL)
1, and IL-6 (Baeuerle and Baltimore, 1996). These media-
tors play important roles in the mediation, propagation, and
extension of a local or systemic inflammatory process and can
cause further activation of NF-B, subsequently increasing
further production of these proinflammatory mediators via
positive feedback mechanisms (Sonis, 2002). Inhibition of
these mediators is beneficial for the treatment of inflamma-
tory diseases and has become an important strategy for sup-
pressing inflammation as is the case in nonsteroidal anti-
inflammatory drugs (Appleby et al., 1994; Bogdan, 2001).
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Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) (PL)
is a naturally occurring yellow pigment found in the plants of
the Plumbaginaceae, Droseraceae, Ancistrocladaceae, and
Dioncophyllaceae families. Available reports on PL have fo-
cused mainly on its anticancer activity and the underlying
mechanisms. Animal and cell studies have demonstrated
that PL has anticancer, antiproliferative, chemopreventive,
radiosensitizing, and antimetastatic activities (Prasad et al.,
1996; Singh and Udupa, 1997; Devi et al., 1998; Sugie et al.,
1998; Wang et al., 2008). Mechanistic studies revealed that
these activities of PL are related to its ability to modulate the
NF-B activation pathway, which in turn induces S-G2/M cell
cycle arrest through the induction of p21 (an inhibitor of
cyclin-dependent kinase) (Jaiswal et al., 2002), changes re-
dox status of cell (Srinivas et al., 2004), and inhibits the
enzyme NADPH oxidase (Ding et al., 2005).
The anti-inflammatory and analgesic activities of leaves of
Plumbago zeylanica and plumbagin have been reported by
Sheeja et al. (2010) in bioassay-guided isolation of anti-in-
flammatory and antinociceptive compound from this plant.
In Sheeja et al.’s report, plumbagin inhibited carrageenan-
induced rat paw edema, prolonged hot plate reaction time in
mice, and shortened duration of pain response in formalin-
induced nociception. However, the mechanism underlying
the anti-inflammatory action of plumbagin remains un-
known. Because NF-B plays a pivotal role in inflammation
and PL has the ability to modulate NF-B in cancer cells, we
therefore hypothesize that PL could suppress experimental
inflammation through the inhibition of NF-B activation.
In this article, the anti-inflammatory activity of PL was
examined in the rat paw edema models induced by commonly
used carrageenan and other phlogistic agents, and the role of
NF-B pathway and the proinflammatory mediators COX,
iNOS, TNF-, IL-1, and IL-6 were examined. In addition,
the analgesic activity of PL was investigated in inflammatory
and noninflammatory pain models. This research will pro-
vide a solid foundation for the use of PL as an anti-inflam-
matory agent for therapeutic purposes.
Materials and Methods
Experimental Animals. Male ICR mice weighing 17 to 23 g and
male SD rats weighing 200 to 250 g were purchased from the Lab-
oratory Animal Services Center, the Chinese University of Hong
Kong, Hong Kong. The animals were acclimated for 1 week under
a 12-h light and 12-h dark cycle at a room temperature of 22°C 
1°C. Chow diet and water were provided ad libitum. Rats and mice
were fasted 24 h before experiment. After completion of experimental
testing, animals were injected with Dorminal, which contains 20%
pentobarbital, and then sacrificed by cervical dislocation. Animal
care and treatment procedures conformed to the Institutional Guide-
lines and Animal Ordinance (Department of Health, Hong Kong
Special Administrative Region).
Drugs and Reagents. Plumbagin (purity 99%), indomethacin,
aspirin, carrageenan, Tween 80, histamine, serotonin, prostaglandin
E2 (PGE2), bradykinin, acetic acid, and magnesium sulfate (MgSO4)
were purchased from Sigma-Aldrich (St. Louis, MO). Rotundine, an
analgesic drug derived from a medical plant in China, was purchased
from Guangzhou Shiqiao Pharmaceutical Co., Ltd., Guangzhou,
China. Morphine hydrochloride injection was purchased from North-
east Pharmaceutical Group Co. (Shenyang, China). Plumbagin, in-
domethacin, and rotundine were dissolved in 100% ethanol and then
resuspended with 0.5% carboxymethyl-cellulose for animal oral ad-
ministration (final concentration of ethanol: 10%). Vehicle was pre-
pared in the same method without drugs added.
Induction of Acute Inflammation in Rat Hind Paws. The
acute inflammation in the hind paws of rats was induced by subcu-
taneous injection of phlogistic agents, including carrageenan, hista-
mine, serotonin, bradykinin, or PGE2, into the right hind paws of
rats according to our previous methods (Zhou et al., 2006). In brief,
two distinct schemes of treatment have been adopted. PL (5, 10, 20
mg/kg), indomethacin (reference drug, 10 mg/kg), or vehicle was
orally administrated 1 h before inflammation induction for the pro-
phylactic scheme. At induction, each rat was injected with freshly
prepared solutions of carrageenan (0.1 ml, 1% w/v), histamine (0.05
ml, 1% w/v), serotonin (0.05 ml, 1% w/v), bradykinin (0.05 ml, 1%
w/v), or PGE2 (20 g in 0.05 ml) in physiological saline (0.9% w/v
NaCl) into subplantar tissues of the right hind paw of rats. In the
therapeutic scheme, the animals received PL (5, 10, and 20 mg/kg),
indomethacin (reference drug, 10 mg/kg), or vehicle 60 min after the
injection of carrageenan. The left hind paws without injection were
used as controls. The volumes (ml) of both hind paws of each animal
were measured with a plethysmometer (7150; UGO Basile, Comerio,
Italy) at 1 h before inflammation induction and at different time
intervals designed from 0.5 to 6 h after injection of the phlogistic
agents. The percentage of increase in paw volume (paw edema) of the
right hind paws of each rat at each time point were calculated by the
following equation: percentage of increase  (A  B)/B  100, where
A represents the paw volumes at different time points after injection,
and B represents the paw volume before injection. At the end of
experiment, the paws injected with carrageenan were collected to
obtain paw exudates. Three to five samples of paw exudates were
randomly selected for Western blot analysis.
Visceral Nociceptive Model Induced by Acetic Acid and
MgSO4 in Mice. The abdominal writhing test induced by chemical
stimulation of acetic acid was performed in mice as described origi-
nally by Siegmund et al. (1957). In brief, PL (5, 10, and 20 mg/kg),
aspirin (200 mg/kg), or vehicle was orally administrated 2 h before
acetic acid injection. After intraperitoneal injection of 0.2 ml of acetic
acid (0.8% w/v) in physiological saline, the animals were isolated for
observation. The numbers of abdominal writhing syndrome/events,
which consisted of the contraction of abdominal area with extension
of hind legs, were accurately recorded during a 15-min period in each
animal.
The abdominal writhing test induced by MgSO4 was performed in
mice as described originally by Gyires and Torma (1984) with minor
modifications. In brief, 1 h before MgSO4 intraperitoneal injection
(120 mg/kg, 10 ml/kg), PL (5, 10, and 20 mg/kg), or vehicle was orally
administrated, and morphine (10 mg/kg) was administrated subcu-
taneously. After intraperitoneal injection of MgSO4, the animals
were isolated in transparent cages for observation. After the first
writhing movement appeared the animals were kept under observa-
tion for 5 min, and the number of writhing movements was counted
during this period.
Central Nociceptive Model Induced by Radiant Heat Stim-
ulation in Rats. The antinociceptive effects of PL and the reference
drug, expressed as the time required for rat tail flick after exposure
to a source of radiant heat, were evaluated according to the descrip-
tion of Zhou et al. (2006). In brief, animals were placed in a Plexiglas
box that allowed their tails to be free, and then the box was placed on
IITC model 336 tail-flick analgesia meter (IITC Inc., Woodland Hills,
CA) with the tail occluding a slit over a photocell for radiant heat
stimulation generated by a power lamp mounted in a reflector. The
tail-flick response was elicited by applying radiant heat to the point
1/3 of length away from the tip of the tail. The apparatus was
arranged so that when the operator turned on the lamp a timer was
activated. When the rat felt pain and flicked its tail, light fell on the
photocell such that the timer was automatically stopped. The inten-
sity of the heat stimulus in the tail-flick test was adjusted so that the
animal flicked its tail within 3 to 5 s. A 20-s cutoff time was set to
prevent tail tissues from damage. Before the experiments, the heat
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stimulation latency of all animals was tested, and those with a
response time to heat stimulation 	2 s or 
6 s were excluded. The
tail-flick response was measured at 1, 2, and 3 h after oral admin-
istration of PL (5, 10, and 20 mg/kg), rotundine (100 mg/kg) as
reference drug, or the vehicle.
Western Blot Analysis of IB, p-NF-B p65, iNOS, COX-1,
COX-2, TNF-, IL-1, and IL-6 Protein Expression. To obtain
paw exudates, the rats were sacrificed by diethyl ether asphyxiation.
Then, each hind paw injected with carrageenan was cut at the level
of the calcaneus bone, and several transversal cuts were made with
a scalpel. Each paw was then centrifuged at 10,000g for 10 min at
4°C to collect tissue exudates (edema fluid). For iNOS, COX-1,
COX-2, TNF-, IL-1, and IL-6 protein analysis, the edema fluid was
vortexed in RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1
mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5
mM sodium pyrophosphate, 1 mM -glycerophosphate, 1 mM
Na3VO4, and 1 g/ml leupeptin) (Cell Signaling Technology, Dan-
vers, MA). For IB and p-NF-B p65 protein analysis, the edema
fluid was vortexed in ice-cold lysis buffer (250 mM sucrose, 50 mM
Tris-HCl, 2 mM sodium EDTA, 2 mM -mercaptoethanol, 5 mM
sodium fluoride, 1 mM sodium orthovanadate, 10 g/ml aprotinin, 10
g/ml leupeptin, pH 7.2) for 1 min. The RIPA or lysis buffer suspen-
sions were immediately centrifuged at 14,000g for 20 min at 4°C, and
the supernatant was gently collected. The contents of total protein in
the supernatants were determined by using a protein kit (Bio-Rad
Laboratories, Hercules, CA). Equal amounts (100 g) of protein were
boiled in sample loading buffer for 5 min before loading on 10%
SDS-polyacrylamide gel for electrophoresis and transferred onto Im-
mobilon-P membrane for blotting (pore size 0.45 m; Millipore Cor-
poration, Billerica, MA). The nonspecific binding sites on the mem-
brane were blocked with 5% nonfat milk in Tris-buffered saline plus
0.1% Tween 20 at 4°C overnight, and then the membranes were
incubated with specific primary antibodies, including IB- (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), p-NF-B p65 (Santa Cruz
Biotechnology, Inc.), iNOS (BD Biosciences, San Jose, CA), COX-1
(Cayman Chemical, Ann Arbor, MI), COX-2 (Cayman Chemical),
TNF- (Cell Signaling Technology), IL-1 (Santa Cruz Biotechnol-
ogy, Inc.), IL-6 (Abcam Inc., Cambridge, MA), and -actin (Santa
Cruz Biotechnology, Inc.). Membranes were subsequently incubated
with peroxidase-conjugated secondary antibodies in 5% nonfat milk
in Tris-buffered saline plus 0.1% Tween 20 for 1 h at room temper-
ature. The membranes were washed six times, and the immunore-
active proteins were detected by enhanced chemiluminescence using
hyperfilm and enhanced chemiluminescence reagent (GE Health-
care, Little Chalfont, Buckinghamshire, UK) according to the man-
ufacturer’s instructions. Band intensities were quantified by using a
densitometer analysis system and expressed as an arbitrary unit
(Quantity One software; Bio-Rad Laboratories).
Statistical Analysis. All values are expressed as means  S.E.M.
Statistical significance of the difference was assessed by repeated
measures analysis of variance, followed by a post hoc test using the
least significant difference method for acute inflammation and tail-
flick test. Statistical significance of the difference was assessed by
one-way analysis of variance followed by a post hoc test with the
least significant difference method for other tests. p values lower
than 0.05 were considered statistically significant.
Results
Plumbagin Inhibited Paw Edema Induced by Differ-
ent Phlogistic Agents in Rats. Figure 1A shows the pro-
phylactic effect of PL on the inhibition of the acute paw
edema in rats evoked by carrageenan injection into the sub-
plantar tissues of right hind paws. The maximum phlogistic
response of carrageenan was observed at 4 to 6 h after the
injection in the control animals. The paw volumes from PL-
treated animals with dosages of 10 and 20 mg/kg at 2 to 6 h
after induction of paw edema showed marked decreases in
comparison with the data of nontreated animals at the same
time points. The reference drug, indomethacin, also signifi-
cantly suppressed the paw edema. Rats treated with 5 mg/kg
PL did not differ from the control group. These results indi-
cate that the antiacute inflammatory effect of PL in rats was
dose-dependent. Figure 1B shows the therapeutic effect of PL
on inhibition of the acute paw edema in rats evoked by
carrageenan. The paw volumes from PL-treated animals
with dosages of 10 and 20 mg/kg showed marked decreases in
comparison with the data of nontreated animals. Indometh-
acin also demonstrated significant suppression to the paw
edema. For the normal group, a very slight increase in paw
Fig. 1. Effect of PL on carrageenan-induced paw edema of rats in prophylactic (A) and therapeutic (B) schemes. The chemical structure of PL is shown
in the A Inset. PL at dosages of 5 (), 10 () and 20 (Œ) mg/kg, the reference drug indomethacin at dosage of 10 mg/kg (‚), and the vehicle (E) were
orally administrated to rats 1 h before carrageenan injection in the prophylactic scheme (A) or 1 h after carrageenan injection in the therapeutic
scheme (B). The percentage of increase in paw volume (paw edema) of the right hind paws of each rat at each time point was calculated by the following
equation: the percentage of increase  (A  B)/B  100, where A represents the paw volumes at different time points after injection, and B represents
the paw volume before injection. Each point represents the mean  S.E.M. (n  9). p value, compared with the vehicle control animals at the
corresponding time point. For the prophylactic scheme, the basal paw volume at 0 h for vehicle, indomethacin, and PL at 5, 10, and 20 mg/ml is 1.53 
0.04, 1.47  0.04, 1.50  0.02, 1.56  0.02, and 1.54  0.03 ml, respectively. For the therapeutic scheme, the basal paw volume at 0 h for vehicle,
indomethacin, and PL at 5, 10, and 20 mg/ml is 1.34  0.04, 1.38  0.01, 1.40  0.03, 1.38  0.02, and 1.38  0.03 ml, respectively. Data represent
the mean  S.E.M.
Plumbagin Suppresses Inflammation via NF-B 737
edema was found at 4 h after 0.1-ml saline injection (2.67 
2.53%; n  3).
In the case of histamine-, serotonin-, bradykinin-, and
PGE2-induced rat paw edema, all measurements were con-
ducted at time intervals of 0.5, 1, 2, 3, and 4 h after injection
of the above phlogistic agents. Figure 2 shows that PL can
dose-dependently inhibit the acute inflammatory responses
evoked by histamine, serotonin, PGE2, or bradykinin. How-
ever, Fig. 2 also shows that the anti-inflammatory effect of
PL, although dose-dependent, also varies according to in-
flammatory agents. In rat paw edema induced by histamine,
bradykinin, and PGE2, the paw volumes from PL-treated
animals with dosages of 10 and 20 mg/kg showed marked
decrease throughout the experiments (Fig. 2, A, C, and D),
whereas, in the paw edema induced by serotonin, only a
higher dose (20 mg/kg) significantly reduced edema (Fig. 2B).
Indomethacin (10 mg/kg) also showed anti-inflammatory ef-
fects in all animals (Fig. 2).
Plumbagin Alleviated Pain Induced by Acetic Acid
but Not MgSO4 and Radiant Heat Stimulation. The
writhing assay induced by peritoneal injection of acetic acid
in mice was used in the study. Figure 3A shows the numbers
of the abdominal writhing episodes evoked by intraperitoneal
injection of acetic acid in mice and the antinociceptive effect
of PL. It can be seen that treatment with PL could dose-
dependently reduce the number of writhing episodes of mice
in comparison with those of vehicle-treated animals, whereas
the reference drug, aspirin, had a stronger effect than PL did.
Figure 3B shows the numbers of the abdominal writhing
episodes evoked by intraperitoneal injection of MgSO4 in
mice. It can be seen that treatment with PL did not reduce
the number of writhing episodes of mice in comparison with
that of vehicle-treated animals, whereas the reference drug,
morphine, had a significant effect in reducing MgSO4-in-
duced writhing episodes.
Table 1 shows that the tail-flick reaction time of the control
animals was approximately 5 s at 1, 2, and 3 h after orally
taking the vehicle. Rats treated with PL did not differ from
the control group, whereas rotundine, a positive analgesic
agent (Zhou et al., 2006), prolonged the reaction time of the
animals and demonstrated significant antinociceptive action.
Fig. 2. Effect of PL on histamine-induced (A), serotonin-induced (B), bradykinin-induced (C), and PGE2-induced (D) paw edema of rats. PL at dosages
of 5 (), 10 (), and 20 (Œ) mg/kg, the reference drug indomethacin at dosage of 10 mg/kg (‚), and the vehicle (E) were orally administrated to rats
1 h before the injection of histamine, serotonin, bradykinin, or PGE2. Each point represents the mean  S.E.M. (n  8–9). p value, compared with the
vehicle control animals at the corresponding time point. For histamine-induced paw edema, the basal paw volume at 0 h for vehicle, indomethacin,
and PL at 5, 10, and 20 mg/ml is 1.47  0.03, 1.54  0.03, 1.47  0.03, 1.57  0.02, and 1.51  0.03 ml, respectively. For serotonin-induced paw edema,
the basal paw volume at 0 h for vehicle, indomethacin, and PL at 5, 10, and 20 mg/ml is 1.35  0.02, 1.34  0.02, 1.31  0.02, 1.32  0.02, and 1.36 
0.04 ml, respectively. For bradykinin-induced paw edema, the basal paw volume at 0 h for vehicle, indomethacin, and PL at 5, 10, and 20 mg/ml is
1.38  0.02, 1.40  0.03, 1.39  0.03, 1.37  0.01, and 1.44  0.03 ml, respectively. For PGE2-induced paw edema, the basal paw volume at 0 h for
vehicle, indomethacin, and PL at 5, 10, and 20 mg/ml is 1.45  0.03, 1.49  0.02, 1.46  0.02, 1.51  0.02, and 1.39  0.03 ml, respectively. Data
represent the mean  S.E.M.
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Plumbagin Suppressed Elevation of iNOS and COX-2 Ex-
pression Induced by Carrageenan in Paw Edema Fluid. It
can be seen in Fig. 4 that PL dose-dependently attenuated the
protein expression of iNOS and COX-2 in carrageenan-in-
jected paw tissues. Approximately 45 and 50% reduction in
iNOS protein expression was achieved by treatment with PL
at dosages of 10 and 20 mg/kg, respectively, whereas no
difference was found at the dosage of 5 mg/kg. Approximately
60 to 70% reduction in COX-2 protein expression was
achieved by treatment with PL at all three dosages. Exami-
nation of COX-1 protein expression showed that the level of
expression was not suppressed by administration of PL at
any dosage. These results suggest that PL may have a selec-
tive inhibitory effect on COX-2 and iNOS protein expression.
However, indomethacin at a dosage of 10 mg/kg demon-
strated significant inhibition on iNOS, COX-1, and COX-2
protein expression. No significant increase in iNOS and
COX-2 protein expression was found in normal animals in
which no carrageenan was injected into the paw.
Plumbagin Reversed Change of IB and p-NF-B
p65 Expression Induced by Carrageenan in Paw Edema
Fluid. The appearance of IB in cell lysate was investigated
by immunoblot analysis. A basal level of IB was detectable
in the normal animals in which no carrageenan was injected
into the paw. At 4 h after carrageenan administration, the
IB level was substantially reduced (Fig. 5) in the control
group. Pretreatment with PL prevented carrageenan-medi-
ated IB degradation. In fact, the IB band intensity of PL
in the pretreatment group remained approximately 50% com-
pared with the normal animals at 4 h after carrageenan
administration (Fig. 5). In carrageenan-treated animals, the
level of p65 NF-B subunit was increased compared with the
normal animals (Fig. 5). However, administration of PL (20
mg/kg) significantly reduced p65 band intensity. The refer-
ence drug indomethacin at 10 mg/kg also reversed the change
of IB and p65 NF-B subunit induced by carrageenan in
the paw edema fluid of rats.
Plumbagin Inhibited Elevation of TNF-, IL-1, and
IL-6 Expression Induced by Carrageenan in Paw
Edema Fluid. The proinflammatory cytokines TNF-, IL-
1, and IL-6 in the carrageenan-injected paw edema fluid
were examined by immunoblot analysis (Fig. 6). A basal level
of TNF- and IL-6 was detectable in the normal group,
whereas IL-1 was not detected in normal rat paw fluid. Four
hours after injection, carrageenan induced an obvious in-
crease in the expression of TNF- and IL-1 and a mild
increase of IL-6 of paw edema fluid. Both PL and indometh-
acin attenuated the increased expression of TNF-, IL-1,
and IL-6.
Discussion
Although PL has been reported to have several biological
functions, mostly related to anticarcinogenic activity (Sugie
et al., 1998; Wang et al., 2008), the anti-inflammatory and
analgesic effect and the underlying mechanism of PL have
not yet been investigated. In the present study, we have
provided the first evidence showing the anti-inflammatory
and analgesic effects of PL in vivo through inhibition of
NF-B activation.
The pharmacological results of our current studies re-
vealed that PL elicited significant anti-inflammatory activi-
ties in the carrageenan model in both prophylactic and ther-
apeutic schemes. PL administrated before or after the
carrageenan injection can still inhibit the paw edema (Fig. 1).
In fact, carrageenan-induced paw edema is one of the most
commonly used models for inflammation investigation. This
model has been widely accepted as a useful phlogistic tool for
new anti-inflammatory agent screening. Development of paw
edema of rats induced by carrageenan is highly correlated
with the early exudative stage of inflammation (Ozaki, 1990).
After carrageenan injection, a sudden elevation of paw vol-
ume can be observed that is correlated with vascular perme-
ability induced by the action of histamine and serotonin
(Vinger et al., 1987). Inflammation begins to be severe at
approximately 1 h after induction, and paw edema gradually
elevates to a peak 4 to 6 h after induction, which is the second
phase caused by the liberation and overproduction of brady-
kinin, prostaglandins, and kinins in paw tissue accompanied
by leukocyte migration (Vinger et al., 1987). The inflamma-
tory pattern in our present study is in close accordance with
Fig. 3. Effect of PL on acetic acid-induced
(A) and MgSO4-induced (B) writhing re-
sponse of mice. PL, the reference drug
aspirin or morphine, and vehicle were
orally administered to mice at 2 h (A) or
1 h (B) before the peritoneal injection of
acetic acid (A) or MgSO4 (B). The number
of writhing episodes of each mouse 15 min
after acetic acid injection was recorded
(A), and the number of writhing episodes
of each mouse was recorded for 5 min
after the first writhing movement ap-
peared (B). Each bar represents the
mean  S.E.M. (n  8–11). , P 	 0.05;
, P 	 0.01; , P 	 0.001, compared
with the vehicle control animals.
TABLE 1
Effect of PL on radiant heat stimulation-induced tail flick reaction
of rat
The tail-flick response was measured at 1, 2, and 3 h after oral administration of PL
(5, 10, and 20 mg/kg), rotundine (100 mg/kg) as reference drug, or vehicle. Data
represent the mean  S.D. (n  8). p value is compared with the vehicle control
animals.
Group Dosage
Tail Flick Reaction Time
p Value
1 h 2 h 3 h
mg/kg
Vehicle 5.8  0.34 5.8  0.57 4.8  0.25
Rotundine 100 15.0  1.76 14.6  1.32 14.8  1.19 	0.001
PL 20 6.1  0.19 6.2  0.46 5.4  0.36 
0.05
PL 10 6.2  0.44 6.2  0.36 5.8  0.41 
0.05
PL 5 5.4  0.27 5.3  0.35 5.2  0.41 
0.05
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previous reports, whereas the dose-dependent inhibition of
inflammation by PL from 1 to 6 h after the induction of
inflammation suggests that PL may act in both the earlier
and later phases of inflammation.
Because PL can inhibit both the first and second phase in
carrageenan-induced edema, these results suggest that the
anti-inflammatory activity of PL could be related to the im-
pairment of proinflammatory mediators in the cyclooxygen-
ase pathway, because most of the nonsteroidal anti-inflam-
matory drugs inhibit the production of proinflammatory
mediators, including eicosanoids. Thus, different inflamma-
tory mediators, i.e., histamine, serotonin, prostaglandin E2,
and bradykinin, were used for paw edema study, so as to
Fig. 4. Effects of PL on iNOS, COX-2, and COX-1 protein expression in
carrageenan-induced paw edema fluid of rats. PL at the dosages of 5, 10,
and 20 mg/kg, the reference drug indomethacin (indo) at dosage of 10
mg/kg, and vehicle were orally administrated 1 h before the carrageenan
injection. Animal without carrageenan injection served as normal control.
At 4 h after the injection, paws were removed and paw edema fluid was
collected by centrifugation. Protein expressions of iNOS, COX-2, and
COX-1 in the paw edema fluid were detected by Western blot analysis
using -actin as the loading control. Each bar represents the mean 
S.E.M. (n  3–5). , P 	 0.05; , P 	 0.001, compared with the vehicle
control animals. #, P 	 0.05, compared with the indomethacin-treated
animals.
Fig. 5. Effects of PL on IB and p-NF-B p65 protein expression in
carrageenan-injected paw edema fluid of rats. The experiment was per-
formed as described in Fig. 4. Protein expressions of IB and p-NF-B
p65 in the paw edema fluid were detected by Western blot analysis using
-actin as the loading control. Indo, indomethacin. Each bar represents
the mean  S.E.M. (n  3–5). , P 	 0.05; , P 	 0.001, compared with
the vehicle control animals.
Fig. 6. Effects of PL on TNF-, IL-6, and IL-1 in carrageenan-injected
paw edema fluid of rats. The experiment was performed as described in
Fig. 4. Protein expressions of TNF-, IL-6, and IL-1 in the paw edema
fluid were detected by Western blot analysis using -actin as the loading
control. Indo, indomethacin.
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further elucidate the anti-inflammatory effect of PL. The
results show that PL had marked dose-dependent inhibitory
effect with different pharmacological intensities on various
inflammatory models induced by histamine, serotonin, pros-
taglandin E2, or bradykinin. The results suggest that the
underlying anti-inflammatory mechanisms of PL are possi-
bly associated with the inhibition of either the synthesis, the
release, or the actions of those proinflammatory mediators.
Analgesic effect usually accompanies anti-inflammation.
We therefore examined the analgesic effect of PL with three
nociceptive animal models: the tail-flick test of rats evoked by
radiant heat stimulation (noxious thermal pain) and acetic
acid- and MgSO4-induced abdominal writhing assay in mice.
The tail-flick test is more sensitive in centrally acting anal-
gesics, whereas the acetic acid-induced abdominal writhing
assay is commonly used for detecting both central and pe-
ripheral analgesia (Dewey et al., 1970; Fukawa et al., 1980;
Won et al., 2006; Schmidt et al., 2009). Acetic acid was
injected into the peritoneal cavity of mice to cause nocicep-
tion in abdomen caused by the release of various substances
that excite pain nerve endings (Raj, 1996). The MgSO4-in-
duced abdominal writhing assay is used as a model of non-
inflammatory, prostaglandin-independent pain reaction.
With the tail-flick test model, it was found that PL did not
have a significant ability of prolonging the response latencies
to the treatment of noxious thermal pain (Table 1). In the
writhing response model, PL showed an ability of diminish-
ing the numbers of writhing episodes in a dose-dependent
manner, indicating a significant inhibition of the acetic acid-
induced visceral nociception, whereas it did not inhibit
MgSO4-induced pain. These results suggest that the analge-
sic effect of PL is prostaglandin-dependent and PL might not
be effective for the treatment of noxious thermal pain. It can
be speculated that PL could inhibit the cyclooxygenase path-
way as shown in Fig. 4, thus further interfering with the
mechanism of transduction in primary afferent nociceptors
in a prostaglandin-dependent manner (Fields, 1987).
In the past two decades, a number of anti-inflammatory
botanical-derived medicines have been developed, but only a
few of them have been studied with the goal of elucidating
the molecular mechanisms of their actions (Surh et al., 2001).
To address this issue, we first evaluated the anti-inflamma-
tory and analgesic properties of PL and then determined the
molecular mechanisms relevant to these actions, focusing on
several key molecular targets, including IB, NF-B,
COX-2, iNOS, and the proinflammatory cytokines TNF-,
IL-1, and IL-6.
It has been widely accepted that the formation of proin-
flammatory cytokines (e.g., TNF-, IL-1, and IL-6) and the
overproduction of vasoactive mediators (e.g., nitric oxide by
iNOS or eicosanoids via COX-2) play important roles in the
pathophysiology of inflammation. The expression of inducible
genes leading to the formation of these proteins relies on
transcription factors, which are either controlled by (other)
inducible genes and, hence, require de novo protein synthesis
or alternatively, by so-called “primary transcription factors.”
Among the latter, NF-B has received a considerable amount
of attention because of its unique mechanism of activation,
active role in cytoplasmic/nuclear signaling, and rapid re-
sponse to pathogenic stimulation. Activation of NF-B is
centrally involved in the local or systemic inflammation (Ru-
etten and Thiemermann, 1997). Binding of NF-B to the
respective binding sequence on genomic DNA encoding for
iNOS, COX-2, TNF, IL-1, and IL-6 results in a rapid and
effective transcription of these genes (Collart et al., 1990; Xie
et al., 1994). The anticarcinogenic, apoptotic, and radiosen-
sitizing effects described previously suggest that PL medi-
ates its effects by suppressing NF-B activation that is
caused by the interaction of PL with the cysteine residue of
both IKK and p65 directly (Sandur et al., 2006). In the
current study, we found that PL indeed suppressed IB
phosphorylation and degradation and, as a result, inhibited
phosphorylation of the p65 subunit of NF-B in carrageenan-
induced paw edema in vivo. This resulted in suppression of
NF-B-regulated reporter gene transcription and gene prod-
ucts involved in inflammation, i.e., TNF-, IL-1, IL-6,
COX-2, and iNOS in this study.
As far as the COXs are concerned, COX-2 is the predominant
cyclooxygenase isoform in all stages of inflammation, including
facilitation of the production of proinflammatory prostanoids
and inflammatory prostaglandins (Vane and Botting, 1998).
Inflammation is induced or potentiated by the overproduction of
prostaglandins (Harris et al., 2002), whereas selective COX-2
inhibitors can suppress inflammatory conditions through inhi-
bition of the inflammatory prostaglandins (Dannenberg et al.,
2001). NO is crucially involved in the regulation of the COX
pathway and can modulate eicosanoid production by acting
at several levels (Mollace et al., 2005). Thus, in inflammatory
conditions where both the iNOS and COX-2 systems are
induced there is a NO-mediated induction of COX-2 leading
to increased formation of proinflammatory prostaglandins.
This results in an exacerbated inflammatory response (Mol-
lace et al., 2005). Thus, inhibition of NO production by the
suppression of the enzyme activity of iNOS is one of the
major pathways for anti-inflammatory effect. Moreover,
Salvemini et al. (1996) reported that peripheral or central
administration of iNOS inhibitors could effectively inhibit
carrageenan-induced hyperalgesia in rats, which means that
NO produced by iNOS is involved in the maintenance of the
carrageenan-evoked inflammatory response. In the present
studies, we demonstrated that PL can significantly suppress
the de novo expressions of inducible NOS and COX-2 en-
zymes, but it cannot inhibit the COX-1 enzyme, which is
believed to be one of the mechanisms by which PL reduces
carrageenan-induced paw edema of rats.
Other than being regulated by NF-B, proinflammatory
cytokines TNF-, IL-1, and IL-6 help to propagate the ex-
tension of a local or systemic inflammatory process by acti-
vating NF-B, forming a positive feedback mechanism to
exaggerate the inflammatory process (Sonis, 2002). IL-1 is a
potent proinflammatory cytokine that exerts its effects by
binding to its receptor (IL1-R1) on the plasma membrane.
This binding induces phosphorylation of the IKK complex, a
crucial step in NF-B activation based on the recruitment of
the IL-1 receptor-associated kinase (Wang et al., 2001). Like
IL-1, TNF- is a potent proinflammatory cytokine that
plays a crucial role in inflammation (Tracey and Cerami,
1993). It binds to its cellular receptor TNF receptor 1, which
triggers signaling cascades that activate NF-B and activa-
tor protein 1 transcription factors. It has also been demon-
strated that IL-6 can induce activation of NF-B in the in-
testinal epithelia (Wang et al., 2003). Therefore, the
inhibition of the production of TNF-, IL-1, and IL-6 by PL
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described in the present study could also likely be attributed
to the inhibitory effect of PL on the activation of NF-B.
In conclusion, PL inhibits NF-B, resulting in a decrease of
the proinflammatory cytokines TNF-, IL-1 and IL-6,
COX-2, and iNOS expression, thus giving its anti-inflamma-
tory effect in animal models. This result suggests that PL has
a potential to be developed into an anti-inflammatory agent
for treating inflammatory diseases.
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